Other Stories

SK Biopharmaceuticals anti-epileptic drug wins FDA approval Updated: 2019-11-22 16:28:21 KST

SK Biopharmaceuticals has announced that its anti-epileptic drug has been granted approval by the U.S. Food and Drug Administration.
Its XCOPRI tablets have been approved to treat partial-onset seizures in adults.
This is the first time a South Korean pharmaceutical company has independently earned FDA approval without a partnership or license.
In a statement, SK Biopharmaceuticals said the FDA approval is a major step toward its goal of becoming a fully integrated global pharmaceutical company that can deliver new treatment options for epilepsy and the central nervous system.
XCOPRI is expected to be available in the United States in the second quarter of 2020.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.